These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 35881312)

  • 21. NF2 mutations are associated with resistance to radiation therapy for grade 2 and grade 3 recurrent meningiomas.
    Vasan V; Dullea JT; Devarajan A; Ali M; Rutland JW; Gill CM; Kinoshita Y; McBride RB; Gliedman P; Bederson J; Donovan M; Sebra R; Umphlett M; Shrivastava RK
    J Neurooncol; 2023 Jan; 161(2):309-316. PubMed ID: 36436149
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple Whole Chromosomal Gains Define Angiomatous Meningiomas and Are Absent From the Tumor Vasculature.
    Ahrendsen JT; Hsu N; Wolf Z; Bryke C; Varma H
    J Neuropathol Exp Neurol; 2020 Jun; 79(6):618-625. PubMed ID: 32357369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrative genomic analysis identifies CCNB1 and CDC2 as candidate genes associated with meningioma recurrence.
    Bie L; Zhao G; Ju Y; Zhang B
    Cancer Genet; 2011 Oct; 204(10):536-40. PubMed ID: 22137483
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas.
    Mawrin C; Sasse T; Kirches E; Kropf S; Schneider T; Grimm C; Pambor C; Vorwerk CK; Firsching R; Lendeckel U; Dietzmann K
    Clin Cancer Res; 2005 Jun; 11(11):4074-82. PubMed ID: 15930342
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical potential of meningioma genomic insights: a practical review for neurosurgeons.
    Karsy M; Azab MA; Abou-Al-Shaar H; Guan J; Eli I; Jensen RL; Ormond DR
    Neurosurg Focus; 2018 Jun; 44(6):E10. PubMed ID: 29852774
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-grade meningiomas: biology and implications.
    Bi WL; Prabhu VC; Dunn IF
    Neurosurg Focus; 2018 Apr; 44(4):E2. PubMed ID: 29606053
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlations between genomic subgroup and clinical features in a cohort of more than 3000 meningiomas.
    Youngblood MW; Duran D; Montejo JD; Li C; Omay SB; Özduman K; Sheth AH; Zhao AY; Tyrtova E; Miyagishima DF; Fomchenko EI; Hong CS; Clark VE; Riche M; Peyre M; Boetto J; Sohrabi S; Koljaka S; Baranoski JF; Knight J; Zhu H; Pamir MN; Avşar T; Kilic T; Schramm J; Timmer M; Goldbrunner R; Gong Y; Bayri Y; Amankulor N; Hamilton RL; Bilguvar K; Tikhonova I; Tomak PR; Huttner A; Simon M; Krischek B; Kalamarides M; Erson-Omay EZ; Moliterno J; Günel M
    J Neurosurg; 2020 Nov; 133(5):1345-1354. PubMed ID: 31653806
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NF2 mutations in secretory and other rare variants of meningiomas.
    Hartmann C; Sieberns J; Gehlhaar C; Simon M; Paulus W; von Deimling A
    Brain Pathol; 2006 Jan; 16(1):15-9. PubMed ID: 16612978
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new amplicon-based gene panel for next generation sequencing characterization of meningiomas.
    Mawrin C; Koch R; Waldt N; Sandalcioglu IE; Braunsdorf WEK; Warnke JP; Goehre F; Meisel HJ; Ewald C; Neyazi S; Schüller U; Kirches E
    Brain Pathol; 2022 Mar; 32(2):e13046. PubMed ID: 35213080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genomic profile of human meningioma cell lines.
    Mei Y; Bi WL; Greenwald NF; Agar NY; Beroukhim R; Dunn GP; Dunn IF
    PLoS One; 2017; 12(5):e0178322. PubMed ID: 28552950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Meningioma: current updates on genetics, classification, and mouse modeling.
    Szulzewsky F; Thirimanne HN; Holland EC
    Ups J Med Sci; 2024; 129():. PubMed ID: 38571886
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence.
    Yesilöz Ü; Kirches E; Hartmann C; Scholz J; Kropf S; Sahm F; Nakamura M; Mawrin C
    Neuro Oncol; 2017 Aug; 19(8):1088-1096. PubMed ID: 28482067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Meningioma genomics: a therapeutic challenge for clinicians.
    Moussalem C; Massaad E; Minassian GB; Ftouni L; Bsat S; Houshiemy MNE; Alomari S; Sarieddine R; Kobeissy F; Omeis I
    J Integr Neurosci; 2021 Jun; 20(2):463-469. PubMed ID: 34258948
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutational Analysis of Recurrent Meningioma Progressing From Atypical to Rhabdoid Subtype.
    Bujko M; Machnicki MM; Grecka E; Rusetska N; Matyja E; Kober P; Mandat T; Rydzanicz M; Płoski R; Krajewski R; Bonicki W; Stokłosa T; Siedlecki JA
    World Neurosurg; 2017 Jan; 97():754.e1-754.e6. PubMed ID: 27756662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrated clinical genomic analysis reveals xenobiotic metabolic genes are downregulated in meningiomas of current smokers.
    Khan AB; Patel R; McDonald MF; Goethe E; English C; Gadot R; Shetty A; Nouri SH; Harmanci AO; Harmanci AS; Klisch TJ; Patel AJ
    J Neurooncol; 2023 Jun; 163(2):397-405. PubMed ID: 37318677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma.
    Ho DM; Hsu CY; Ting LT; Chiang H
    Cancer; 2002 Mar; 94(5):1538-47. PubMed ID: 11920512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemotherapy and targeted therapies for meningiomas: what is the evidence?
    Graillon T; Tabouret E; Chinot O
    Curr Opin Neurol; 2021 Dec; 34(6):857-867. PubMed ID: 34629433
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progestin-associated shift of meningioma mutational landscape.
    Peyre M; Gaillard S; de Marcellus C; Giry M; Bielle F; Villa C; Boch AL; Loiseau H; Baussart B; Cazabat L; Raffin-Sanson ML; Sanson M; Kalamarides M
    Ann Oncol; 2018 Mar; 29(3):681-686. PubMed ID: 29206892
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathological classification and molecular genetics of meningiomas.
    Mawrin C; Perry A
    J Neurooncol; 2010 Sep; 99(3):379-91. PubMed ID: 20809251
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas.
    Boetto J; Bielle F; Sanson M; Peyre M; Kalamarides M
    Neuro Oncol; 2017 Mar; 19(3):345-351. PubMed ID: 28082415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.